Dispensing device

ABSTRACT

The present invention relates to a method of dispensing a liquid suspension from a reservoir of a liquid suspension held in a delivery system, wherein the reservoir of liquid suspension is of a type which is normally isolated from atmosphere, comprising the steps of: a) increasing the volume of the reservoir above an initial volume so as to reduce the pressure in the reservoir to below atmospheric; b) agitating the liquid suspension; c) reducing the volume of the reservoir to the initial volume; and d) subsequently dispensing at least a portion of the liquid suspension from the reservoir.

The invention relates to dispensing devices and, particularly todispensing devices for dispensing medicaments in suspension in a sprayform.

Delivery systems are known for administering liquids in spray form. Onesuch system is described in published application WO91/15303. A problemhas been found with dispensing liquids, including medicaments, which areformed from suspensions using such devices. It is a requirement of suchdevices that the liquid medicament is stored without any air beingpresent in the medicament cartridge or medicament vial. This is due tothe fact that the air can cause degradation of the medicament, becauseof the dangers of injecting air into the patient, especially where themedicament is used intravenously, and also the inconsistency in shotweight which occurs when air is present. As a result, the vials orcartridges or other containers for the medicament are formed with no airspace. A problem has been found with dispensing suspensions from suchvials or cartridges since it has been found that over time, thesuspended element of the suspension settles out from the liquid carrier.In order for a correct dosage to be dispensed, it is therefore necessaryto agitate the medicament to resuspend the medicament in the liquidcarrier. This is not easy to achieve efficiently with many suspensionsin a medicament vial or cartridge where there is no air space or otherhead space.

The present invention provides a method of dispensing a liquidsuspension from a reservoir of a liquid suspension held in a deliverysystem, wherein the reservoir of liquid suspension is of the type whichis normally isolated from atmosphere, comprising the steps of:

-   -   a) increasing the volume of the reservoir above an initial        volume so as to reduce the pressure in the reservoir to below        atmospheric;    -   b) agitating the liquid suspension;    -   c) reducing the volume of the reservoir to the initial volume;        and    -   d) subsequently dispensing at least a portion of the liquid        suspension from the reservoir.

The present invention also provides a delivery system for dispensing aliquid suspension comprising a reservoir of the liquid suspension of thetype which is normally isolated from atmosphere, means for creating atleast a partial vacuum in the reservoir of liquid suspension and meansfor dispensing at least a portion of the liquid from the reservoirsubsequent to agitation of the liquid suspension.

The present invention also provides use of the delivery system.

An embodiment of the present invention will now be described, by way ofexample only, with reference to the accompanying drawing, which is asectional elevation through a dispensing device according to theinvention.

Referring to FIG. 1, there is illustrated a dispensing device intendedfor dispensing a liquid medicament in the form of a spray. The deviceforms a delivery system which is particularly suitable for nasaladministration of a medicament.

The dispensing device comprises a drive unit 10, a dispenser housing 11,a nozzle 143 and a protective cap 170.

The dispenser housing 11 is a cylindrical tube. A generally cylindricalhousing 141 is received slidingly inside, and connected to, thedispenser housing 11 by means of a snap-fit co-operating feature 62. Thegenerally cylindrical housing 141 has a stepped end 142 which isgenerally closed off and connects to the nozzle 143 of the device andincludes at its other end a piston 22 which is sealingly received in thecartridge 141 so as to isolate the contents of the cartridge 141 fromatmosphere when the nozzle 143 is in the closed position. The drive unit10 is arranged to move the piston 22 to the left as viewed in FIG. 1 bypre-selected distances corresponding to pre-selected doses of medicamentstored in the device which are to be dispensed. The operation of thedrive unit 10 will be described further below.

The stepped end 142 of the generally cylindrical housing 141, whichserves as a medicament cartridge, is closed off by a valve cap 145having a central aperture 146 fixed to the end of the cartridge 141 andtrapping a valve seat 147 between the valve cap 145 and the open end ofstepped portion 142 of the cartridge 141.

The nozzle 143 of the device comprises outer and inner nested components149 and 150 which define between them a flow path for medicament to bedispensed. The nozzle 143 is of the type designed to dispense apressurised liquid passing through the nozzle in the form of a spray.The construction of the nozzle 143 may be, for example, as described inpublished European patent application 0 308 100. In summary, an axiallyextending channel 152 is defined between the inner and outer components149, 150 leading to a swirl chamber 153 and outlet orifice 154 of thedevice. The inner end of the inner nested component 150 includes atapered peg 156 which is fitted in a tapered bore of a valve core 158.The valve core 158 includes an enlarged portion 159, the shoulder ofwhich engages the valve seat 147 to isolate the contents of cartridge141 from the atmosphere when the device is not in use.

When the portion 159 is unseated from valve seat 147, medicament mayflow into the nozzle 143 through side holes 160 in the valve core 158and thence through a flow path formed between tapered peg 156 and thebore in which it seats. This connects in turn with axial bore 152 innozzle 143.

The inner and outer nested components 149, 150 of the nozzle 143 and thevalve core 158 are fixed together to move as a single component. Theassembly of nozzle and valve core is moved by a slider 162 includingfinger grips 163 which is fixed to a skirt portion 164 of the outercomponent 149 of the nozzle assembly. As shown in FIG. 1, the attachmentof the slider 162 to the skirt portion 164 is by means of aninter-engaging annular bead and groove 166, 167 which snap-fit together.The assembly of nozzle 143 and valve stem 158 is urged into its normallyclosed position by spring 169 located between an inner surface of outernozzle component 149 and valve cap 145.

The dispensing device 140 also includes a cap 170 which fits over thecartridge 141 enclosing the nozzle assembly 143 and includes a clip 171similar to a pen cap.

In use of the device 140, the cap 170 is first removed. The device isthen pre-loaded (as will be described below) to dispense a pre-selectedquantity of medicament by selecting the required dose on the drive unit10. The user then applies nozzle 143 to the point at which themedicament is to be introduced (for example, a nostril) and slides theslider 162 relative to the cartridge 141 thereby unseating the valvestem 158 from the valve seat 147 and allowing a portion of themedicament stored in the reservoir of the cartridge 141 to be dispensed.

The drive unit 10 of the dispensing device is located in housing 11. Theend of housing 11 remote from nozzle 143 is closed off a cap 44. Thehousing 11 is open at the other end 61 for receiving the cartridge 141as described above. A plunger 40 extends from end cap 44 towards pistonmember 22 and the drive unit 10 is operable to cause the plunger 40 tomove axially towards nozzle 143 by a fixed distance determined by a doseselector (not shown) which is incorporated in end cap 44. The end cap 44is rotatably mounted on the end of the housing 11 remote from plunger40. Axial movement of the plunger 40 by said fixed distance causes thepiston 22 to be urged to move the same distance to dispense the selecteddose of the liquid medicament as described above.

The plunger 40 has an integrally formed thread 45 of a large lead angle.The plunger 40 slides axially within a plunger guide 43 which comprisesinwardly directed teeth 49 which engage the thread 45 of the plunger 40.The plunger guide 43 is coupled to end cap 44 by co-operating bead andgroove formations 54 and 53 which snap-fit together. The plunger guide43 is rotatably fixed relative to the end cap 44 such that rotation ofend cap 44 causes plunger guide 43 also to rotate. Rotation of plungerguide 43 in turn urges plunger 40 to move axially towards nozzle 143 bymeans of the engagement between teeth 49 and thread 45.

The plunger guide 43 comprises a number of circumferentially spaced ribs51 which extend from an outer surface of the plunger guide 43 towardsthe inner wall of housing 11. The inner wall of housing 11 is providedwith a matching number of T-shaped channels 52 in which the distal edgesof ribs 51 are received. As shown in FIG. 1, the channels 52 extendaxially from open end 61 to a point axially to the right of ribs 51 whenin the position shown in FIG. 1.

A spring 48 is provided seated between an end face of the ribs 51nearest of the end cap 44 and a spring seat 50 provided on an inwardlydirected flange of the housing 11. The spring 48 acts to urge theplunger guide 43 towards the left as shown in FIG. 1.

The plunger guide 43 further comprises an end face 71 directed towardsnozzle 143 which is provided with a series of teeth (not shown) whichengage matching teeth on a ratchet disc 72 located between the plungerguide 43 and the cartridge 141. The ratchet disc 72 is rotationallyfixed relative to cartridge 141. The matching sets of teeth are directedrelative to one another such that relative rotation between the plungerguide 43 and the ratchet disc 72 is possible in only one direction.

In use to dispense a dose the end cap 44 is rotated which in turnrotates plunger guide 4.3 and also housing 11 by means of the engagementof the ribs 51 in the channels 52. The ratchet disc 72 and teeth on theend face 71 of the plunger guide 43 prevent rotation of the plungerguide 43 in the opposite direction. Rotation of the plunger guide 43acts on the thread 45 of the plunger 40 through the teeth 49. Due to theincompressibility of the liquid medicament 21, the piston member 22 isunable to move towards the left as shown in FIG. 1 whilst the nozzle 143is in the closed position. Hence, rotation of end cap 44 causes theplunger guide 43 and end cap 44 to move to the right as shown in FIG. 1so as to accommodate the relative rotational movement between the thread45 and teeth 49. As a result, the end cap 44, plunger guide 43 and ribs51 move towards the right as shown in FIG. 1, compressing the spring 48between the end face of ribs 51 and the spring seat 50 so as to chargethe drive unit 10 with stored, spring energy. Co-operating formation 62prevents housing 11 moving to the left as viewed in FIG. 1 under actionof spring 48 as the spring force of spring 48 is insufficient to unseatthe co-operating formation 62. An end face 55 of the T-shaped channels52 acts as a limiter on the axial movement of the ribs 51 towards theright as shown in FIG. 1 so as to limit the energy stored in spring 48.Alternatively, the dose selector incorporated in end cap 44 may comprisemeans for limiting the rotation of end cap 44 during charging.

Once charged, the nozzle 143 is operated as described above by movementof the slider 162. At the point when the flow path to the outlet orifice145 opens, the liquid medicament 21 is able to be dispensed,accommodating movement of the piston member to the left as shown inFIG. 1. At this point, spring 48 urges the ribs 51, plunger guide 43,dose selector 44 and plunger 40 to move to the left with piston member22 to dispense the pre-selected dose of liquid medicament 21. The deviceis then ready to be re-charged for a subsequent actuation.

A problem has been found with dispensing liquid medicaments which areformed from suspensions using devices such as the one described above.It is a requirement of such devices that the liquid medicament 21 isstored without any air being present in the medicament cartridge 141 ormedicament vial. This is due to the fact that the air can causedegradation of the medicament, because of the dangers of injecting airinto the patient, especially where the medicament 21 is usedintravenously, and also the inconsistency in shot weight which occurswhen air is present. As a result, the vials or cartridges or othercontainers for the medicament 21 are formed with no air space. A problemhas been found with dispensing suspensions from such vials or cartridgessince it has been found that over time, the suspended element of thesuspension settles out from the liquid carrier. In order for a correctdosage to be dispensed, it is therefore necessary to agitate themedicament to resuspend the medicament in the liquid carrier. This isnot easy to achieve efficiently with many suspensions in a medicamentvial or cartridge where there is no air space or other head space,especially where the user is elderly or infirm.

The present invention overcomes this problem by providing means forcreating a vacuum or partial vacuum in the normally air free medicamentvial or cartridge.

Referring to FIG. 1, a portion of the cartridge 141 is provided with anexternal screw thread on which is mounted a threaded nut 60 which abutsthe open end 61 of the housing 11. In addition, end cap 44 is providedwith a circumferential channel 63 in which is received the opposite endof the housing 11. In use, before operating the end cap 44 to charge thedevice for dispensation, the threaded nut 60 is rotated so as to movethe threaded nut 60 to the right as viewed in FIG. 1 along the externalthread of the cartridge 141. The movement of the threaded nut 60 to theright as shown in FIG. 1 forces the housing 11 and, by means of theengagement of the end of housing 11 in the circumferential channel 63,the end cap 44 to the right as viewed in FIG. 1. The rotation of the nut60 provides sufficient force to unseat the co-operating formation 62 toallow the housing 11 to slide axially relative to the cartridge 141. Themovement of the housing 11 in turn causes the piston member 22 to bemoved to the right as viewed in FIG. 1 due to the engagement of theplunger 40, piston guide 43 and end cap 44. Consequently, operation ofthe threaded nut 60 produces an increase in volume of the cartridge andat the same time a reduction in pressure in the cartridge 141 belowatmospheric since, with the nozzle 143 closed, the cartridge 141 isisolated from atmosphere. As such, a partial vacuum is created in thecartridge 141. The user then agitates the cartridge 141 by shaking thedevice to resuspend the suspension. The threaded nut 60 is then rotatedin the opposite sense to return it to its original position. At the sametime the suction effect of the partial vacuum in the cartridge 141 drawsthe piston member 22 back to its original position causing theco-operating formation 62 to re-engage. To aid re-engagement the facesof the co-operating formation contacting one another on re-engagementmay be tapered so as to urge the formations to ride over one another.

Once the co-operating formations 62 are re-engaged, the device is readyto be charged and fired in the same manner as described above.

The present invention is not limited to the device described above whichis provided as merely an illustrative example. The present inventionprovides equal application with both single dose and multiple dosedevices. The medicament may be provided in a replaceable cartridge, vialor other container. Alternatively, the medicament may be provided in achamber formed as part of the housing of the device, especially wherethe device is a single dose dispenser.

Other drive units may be used to power the dispensation of themedicament. One example is described in published European Patentapplication 0338806.

Other means of sealing the nozzle 143 and other nozzle types may be usedwithout departing from the scope of the present invention.

The delivery system may be adapted for other types of administration,for example oral or sub-lingual.

1. A composition for treating skin ailments treatments selected from agroup consisting of bruises, scars, cold sores, eczema, rosacea,shingles, muscular joints and aches, moles, acne, rashes, insect bites,psoriasis, dry itchy scaly skin, skin discoloration, blisters, burns,bee stings, athletes foot, boils, chapped hands and lips, cuts andscrapes and herpes simplex, comprising: active agents and a carriermixture, wherein said active agents are herbal extracts in a therapeuticeffective dose, wherein said herbal extract is selected from the groupconsisting of mallow extract, rosemary extract and eucalyptus extractand said active agent mixes with carrier mixture for administration ofsaid composition.
 2. A composition as claimed in claim 1, consisting ofthe following ingredients in the following percentage range by weight:(a) Water in the range of 40.19-49.12 (b) Sodium laureth sulphate in therange of 31.5-38.5 (c) Cocamide DEA in the range of 4.5-5.5 (d)Cocamidopropyl betaine in the range of 0.9-1.1 (e) Proylene glycol inthe range of 0.27-0.33 (f) Citric acid in the range of 0.27-0.33 (g)Coal tar topical solution in the range of 5.4-6.6 (h) Sodium chloride inthe range of 1.8-2.2 (i) Sodium layroyl sarcosinate in the range of1.8-2.2 (j) Wheat germ oil in the range of 0.45-0.55 (k) Proteins(blends) in the range of 0.18-0.22 (l) Methylchloroisothiazolinone inthe range of 0.045-0.045 (m) Mallow extract in the range of 0.9-1.1 (n)Rosemary oil in the range of 0.45-0.55 (o) Eucalyptus oil in the rangeof 0.45-0.55 (p) Carbomer in the range of 0.9-1.1.
 3. A composition asclaimed in claim 1 for treating skin ailments selected from a groupconsisting of bruises, scars, cold sores, eczema, rosacea, shingles,muscular joints and aches, moles, acne, rashes, insect bites, psoriasis,dry itchy scaly skin, skin discoloration, blisters, burns, bee stings,athletes foot, boils, chapped hands and lips, cuts and scrapes andherpes simplex consisting of the following ingredients in the followingpercentage range by weight; (a) Water in the range of 21.573-26.367 (b)Alcohol in the range of 63-77 (c) Sodium Iodide in the range of 2.7-3.3(d) Potassium iodide in the range of 1.35-1.65 (e) Sodium thiosulphatein the range of 0.027-0.033 (f) Mallow extract in the range of 0.9-1.1(g) Rosemary oil in the range of 0.225-0.27 (h) Eucalyptus oil in therange of 0.225-0.27.
 4. A composition as claimed in claim 1 consistingof the following ingredients in the following percentage range byweight: (a) Water in the range of 47.0205-57.4695 (b) Propylene glycolin the range of 3.6-4.4 (c) Mineral oil in the range of 2.7-3.3 (d)Cetyl alcohol in the range of 3.6-4.4 (e) Stearic acid in the range of3.6-4.4 (f) Glycerol monostearate in the range of 2.7-3.3 (g) F D and CYellow #5 solution in the range of 0.045-0.055 (h) D and C red #33solution in the range of 0.0045-0.055 (i) Chamomile extract in the rangeof 0.9-1.1 (j) Carbomer in the range of 3.6-4.4 (k) Methyl paraben inthe range of 0.225-0.275 (l) Propyl paraben in the range of 0.09-0.11(m) Triethanolamine in the range of 0.54-0.66 (n) Milk amino acids inthe range of 2.25-2.75 (o) Tea tree solution in the range of 2.7-3.3 (p)Mallow extract in the range of 0.9-1.1 (q) Coal tar topical solution inthe range of 5.175-6.325 (r) Dimethicone in the range of 0.45-0.55 (s)Glycerine in the range of 2.7-3.3 (t) Petrolatum in the range of 0.9-1.1(u) Cetearyl alcohol in the range of 2.25-2.75 (v) Ceteareth 20 in therange of 2.25-2.75 (w) Polysorbate 20 in the range of 1.8-2.2.
 5. Acomposition as claimed in claim 1 consisting of at least 5% herbalextracts in an effective skin ailment treatment percentage mixed with acarrier mixture for topical administration to a human.
 6. A compositionas claimed in claim 1 for use in the treatment of skin ailments aswherein said herbal extract is least one percent mallow extract.
 7. Asystem for use in skin ailment treatments selected from a groupconsisting of bruises, scars, cold sores, eczema, rosacea, shingles,muscular joints and aches, moles, acne, rashes, insect bites, psoriasis,dry itchy scaly skin, skin discoloration, blisters, burns, bee stings,athletes foot, boils, chapped hands and lips, cuts and scrapes andherpes simplex, comprising a body wash composition, a spray compositionand a cream composition, wherein said body wash composition, said spraycomposition and said cream composition further comprises an active agentand carrier mixture, wherein said active agents are herbal extracts in atherapeutic effective does, and said active agents mixes with saidcarrier mixture for administration of said body wash composition, saidspray composition and said cream composition.
 8. A system for use inskin ailment treatments as claimed in claim 7 wherein said body washcomposition consisting of the following ingredients in the followingrange of proportions based on weight: (a) Water in the range of40.19-49.12 (b) Sodium laureth sulphate in the range of 31.5-38.5 (c)Cocamide DEA in the range of 4.5-5.5 (d) Cocamidopropyl betaine in therange of 0.9-1.1 (e) Proylene glycol in the range of 0.27-0.33 (f)Citric acid in the range of 0.27-0.33 (g) Coal tar topical solution inthe range of 5.4-6.6 (h) Sodium chloride in the range of 1.8-2.2 (i)Sodium layroyl sarcosinate in the range of 1.8-2.2 (j) Wheat germ oil inthe range of 0.45-0.55 (k) Proteins (blends) in the range of 0.18-0.22(l) Methylchloroisothiazolinone in the range of 0.045-0.045 (m) Mallowextract in the range of 0.9-1.1 (n) Rosemary oil in the range of0.45-0.55 (o) Eucalyptus oil in the range of 0.45-0.55 (p) Carbomer inthe range of 0.9-1.1.
 9. A system for use in skin ailment treatments asclaimed in claim 7 wherein said spray composition consisting of thefollowing ingredients in the following range of proportions based onweight: (a) Water in the range of 21.573-26.367 (b) Alcohol in the rangeof 63-77 (c) Sodium Iodide in the range of 2.7-3.3 (d) Potassium iodidein the range of 1.35-1.65 (e) Sodium thiosulphate in the range of0.027-0.033 (f) Mallow extract in the range of 0.9-1.1 (g) Rosemary oilin the range of 0.225-0.27 (h) Eucalyptus oil in the range of0.225-0.27.
 10. A system for use in skin ailment treatments as claimedin claim 7 wherein said cream composition consisting of the followingingredients in the following range of proportions: (a) Water in therange of 47.0205-57.4695 (b) Propylene glycol in the range of 3.6-4.4(c) Mineral oil in the range of 2.7-3.3 (d) Cetyl alcohol in the rangeof 3.6-4.4 (e) Stearic acid in the range of 3.6-4.4 (f) Glycerolmonostearate in the range of 2.7-3.3 (g) F D and C Yellow #5 solution inthe range of 0.045-0.055 (h) D and C red #33 solution in the range of0.0045-0.055 (i) Chamomile extract in the range of 0.9-1.1 (j) Carbomerin the range of 3.6-4.4 (k) Methyl paraben in the range of 0.225-0.275(l) Propyl paraben in the range of 0.09-0.11 (m) Triethanolamine in therange of 0.54-0.66 (n) Milk amino acids in the range of 2.25-2.75 (o)Tea tree solution in the range of 2.7-3.3 (p) Mallow extract in therange of 0.9-1.1 (q) Coal tar topical solution in the range of5.175-6.325 (r) Dimethicone in the range of 0.45-0.55 (s) Glycerine inthe range of 2.7-3.3 (t) Petrolatum in the range of 0.9-1.1 (u) Cetearylalcohol in the range of 2.25-2.75 (v) Ceteareth 20 in the range of2.25-2.75 (w) Polysorbate 20 in the range of 1.8-2.2.
 11. A method oftreating skin ailments selected from a group consisting of bruises,scars, cold sores, eczema, rosacea, shingles muscular joints and aches,moles, acne, rashes, insect bites, psoriasis, dry itch scaly skin, skindiscoloration, blisters, burns, bee stings, athletes foot, boils,chapped hands and lips, cuts and scrapes and herpes simplex, comprisingtopically administering to a human having said skin ailment at least 1%herbal extracts, said herbal extracts being present in a topicallyacceptable pharmaceutical body wash composition.
 12. A method as claimedin claim 11 wherein said topically acceptable pharmaceutical body washcomposition consisting of the following ingredients in the followingrange of proportions: (a) Water in the range of 40.19-49.12 (b) Sodiumlaureth sulphate in the range of 31.5-38.5 (c) Cocamide DEA in the rangeof 4.5-5.5 (d) Cocamidopropyl betaine in the range of 0.9-1.1 (e)Proylene glycol in the range of 0.27-0.33 (f) Citric acid in the rangeof 0.27-0.33 (g) Coal tar topical solution in the range of 5.4-6.6 (h)Sodium chloride in the range of 1.8-2.2 (i) Sodium layroyl sarcosinatein the range of 1.8-2.2 (j) Wheat germ oil in the range of 0.45-0:55 (k)Proteins (blends) in the range of 0.18-0.22 (l)Methylchloroisothiazolinone in the range of 0.045-0.045 (m) Mallowextract in the range of 0.9-1.1 (n) Rosemary oil in the range of0.45-0.55 (o) Eucalyptus oil in the range of 0.45-0.55 (p) Carbomer inthe range of 0.9-1.1.
 13. A method treating skin ailments selected froma group consisting of bruises, scars, cold sores, eczema, rosacea,shingles, muscular joints and aches, moles, acne, rashes, insect bites,psoriasis, dry itchy scaly skin, skin discoloration, blisters, burns,bee stings, athletes foot, boils, chapped hands and lips, cuts andscrapes and herpes simplex, comprising topically administering to ahuman having said skin ailment, at least 1% herbal extracts, said herbalextracts being present in a topically acceptable pharmaceutical spraycomposition.
 14. A method of treating skin ailments as claimed in claim13 wherein said topically acceptable pharmaceutical spray compositionconsisting of the following ingredients in the following range ofproportions: (a) Water in the range of 21.573-26.367 (b) Alcohol in therange of 63-77 (c) Sodium Iodide in the range of 2.7-3.3 (d) Potassiumiodide in the range of 1.35-1.65 (e) Sodium thiosulphate in the range of0.027-0.033 (f) Mallow extract in the range of 0.9-1.1 (g) Rosemary oilin the range of 0.225-0.27 (h) Eucalyptus oil in the range of0.225-0.27.
 15. A method of treating skin ailments selected from thegroup consisting of bruises, scars, cold sores, eczema, rosacea,shingles, muscular joints and aches, moles, acne, rashes, insect bites,psoriasis, dry itchy scaly skin, skin discoloration, blisters, burns,bee stings, athletes foot, boils, chapped hands and lips, cuts andscrapes and herpes simplex, comprising topically administering to ahuman having said skin ailment at least 1% herbal extracts, said herbalextracts being present in a topically acceptable pharmaceutical creamcomposition.
 16. A method of treating skin ailments as claimed in claim15 wherein said topically acceptable pharmaceutical cream compositionconsisting of the following ingredients in the following range ofproportions: (a) Water in the range of 47.0205-57.4695 (b) Propyleneglycol In the range of 3.6-4.4 (c) Mineral oil in the range of 2.7-3.3(d) Cetyl alcohol in the range of 3.6-4.4 (e) Stearic acid in the rangeof 3.6-4.4 (f) Glycerol monostearate in the range of 2.7-3.3 (g) F D andC Yellow #5 solution in the range of 0.045-0.055 (h) D and C red #33solution in the range of 0.0045-0.055 (i) Chamomile extract in the rangeof 0.9-1.1 (j) Carbomer in the range of 3.6-4.4 (k) Methyl paraben inthe range of 0.225-0.275 (l) Propyl paraben in the range of 0.09-0.11(m) Triethanolamine in the range of 0.54-0.66 (n) Milk amino acids inthe range of 2.25-2.75 (o) Tea tree solution in the range of 2.7-3.3 (p)Mallow extract in the range of 0.9-1.1 (q) Coal tar topical solution inthe range of 5.175-6.325 (r) Dimethicone in the range of 0.45-0.55 (s)Glycerine in the range of 2.7-3.3 (t) Petrolatum in the range of 0.9-1.1(u) Cetearyl alcohol in the range of 2.25-2.75 (v) Ceteareth 20 in therange of 2.25-2.75 (w) Polysorbate 20 in the range of 1.8-2.2.
 17. Amethod for treating skin ailments selected from a group consisting ofbruises, scars, cold sores, eczema, rosacea, shingles, muscular jointsand aches, moles, acne, rashes, insect bites, psoriasis, dry itch scalyskin, skin discoloration, blisters, burns, bee stings, athletes foot,boils, chapped hands and lips, cuts and scrapes and herpes simplex,comprising topically administering to a human having said skin ailmentsat least 1% herbal extracts, said herbal extracts being present in atopically acceptable pharmaceutical body wash composition, spraycomposition and cream composition.
 18. A method for treating skinailments as claimed in claim 17 wherein said body wash compositionconsisting of the following ingredients in the following range ofproportions: (a) Water in the range of 40.19-49.12 (b) Sodium laurethsulphate in the range of 31.5-38.5 (c) Cocamide DEA in the range of4.5-5.5 (d) Cocamidopropyl betaine in the range of 0.9-1.1 (e) Proyleneglycol in the range of 0.27-0.33 (f) Citric acid in the range of0.27-0.33 (g) Coal tar topical solution in the range of 5.4-6.6 (h)Sodium chloride in the range of 1.8-2.2 (i) Sodium layroyl sarcosinatein the range of 1.8-2.2 (j) Wheat germ oil in the range of 0.45-0.55 (k)Proteins (blends) in the range of 0.18-0.22 (l)Methylchloroisothiazolinone in the range of 0.045-0.045 (m) Mallowextract in the range of 0.9-1.1 (n) Rosemary oil in the range of0.45-0.55 (o) Eucalyptus oil in the range of 0.45-0.55 (p) Carbomer inthe range of 0.9-1.1.
 19. A method for treating skin ailments as claimedin claim 18 wherein said spray composition consisting of the followingingredients in the following range of proportions; (a) Water in therange of 21.573-26.367 (b) Alcohol in the range of 63-77 (c) SodiumIodide in the range of 2.7-3.3 (d) Potassium iodide in the range of1.35-1.65 (e) Sodium thiosulphate in the range of 0.027-0.033 (f) Mallowextract in the range of 0.9-1.1 (g) Rosemary oil in the range of0.225-0.27 (h) Eucalyptus oil in the range of 0.225-0.27.
 20. A methodof treating skin ailments as claimed in claim 19, wherein said creamcomposition consisting of the following ingredients in the followingrange of proportions: (a) Water in the range of 47.0205-57.4695 (b)Propylene glycol in the range of 3.6-4.4 (c) Mineral oil in the range of2.7-3.3 (d) Cetyl alcohol in the range of 3.6-4.4 (e) Stearic acid inthe range of 3.6-4.4 (f) Glycerol monostearate in the range of 2.7-3.3(g) F D and C Yellow #5 solution in the range of 0.045-0.055 (h) D and Cred #33 solution in the range of 0.0045-0.055 (i) Chamomile extract inthe range of 0.9-1.1 (j) Carbomer in the range of 3.6-4.4 (k) Methylparaben in the range of 0.225-0.275 (l) Propyl paraben in the range of0.09-0.11 (m) Triethanolamine in the range of 0.54-0.66 (n) Milk aminoacids in the range of 2.25-2.75 (o) Tea tree solution in the range of2.7-3.3 (p) Mallow extract in the range of 0.9-1.1 (q) Coal tar topicalsolution in the range of 5.175-6.325 (r) Dimethicone in the range of0.45-0.55 (s) Glycerine in the range of 2.7-3.3 (t) Petrolatum in therange of 0.9-1.1 (u) Cetearyl alcohol in the range of 2.25-2.75 (v)Ceteareth 20 in the range of 2.25-2.75 (w) Polysorbate 20 in the rangeof 1.8-2.2.